Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Xbiotech Inc (XBIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 157,786
  • Shares Outstanding, K 35,220
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,760 K
  • 36-Month Beta 0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.77 +82.99%
on 06/09/17
11.85 -57.23%
on 06/02/17
-3.39 (-40.09%)
since 05/22/17
3-Month
2.77 +82.99%
on 06/09/17
20.18 -74.88%
on 03/27/17
-13.70 (-73.00%)
since 03/22/17
52-Week
2.77 +82.99%
on 06/09/17
25.00 -79.73%
on 07/01/16
-11.68 (-69.74%)
since 06/22/16

Most Recent Stories

More News
Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines

PALM BEACH, Florida, June 13, 2017 /PRNewswire/ --

AGEN : 4.10 (+4.06%)
TROV : 1.11 (+16.84%)
XBIT : 4.99 (+11.38%)
GTXI : 4.46 (+3.72%)
MBRX : 0.98 (-5.77%)
Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines

In just over a year ago, it's been estimated $50 billion was invested on pharmaceutical Research and Development activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected...

AGEN : 4.10 (+4.06%)
TROV : 1.11 (+16.84%)
XBIT : 4.99 (+11.38%)
MBRX : 0.98 (-5.77%)
GTXI : 4.46 (+3.72%)
XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis

AUSTIN, Texas, June 09, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that an Independent Data Monitoring Committee (IDMC) has performed its second prospectively planned, unblinded...

XBIT : 4.99 (+11.38%)
XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis

XBiotech Inc. (NASDAQ:XBIT) announced today that an Independent Data Monitoring Committee (IDMC) has performed its second prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company's...

XBIT : 4.99 (+11.38%)
Why XBiotech Inc. (XBIT) Could Shock the Market Soon

Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for XBiotech (XBIT) and that now might be an interesting buying opportunity.

XBIT : 4.99 (+11.38%)
Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer

XBiotech Inc. (NASDAQ:XBIT) announced today an upcoming presentation of findings on key biomarker analysis of colorectal cancer patients treated with Hutruo (MABp1) in its European Phase III study. The...

XBIT : 4.99 (+11.38%)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT

Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. ("XBiotech") (NASDAQ: XBIT) concerning possible violations of federal securities laws.

XBIT : 4.99 (+11.38%)
XBiotech to Provide First Quarter 2017 Business Update

XBiotech Inc. (NASDAQ:XBIT) announced today it will host a conference call and live audio webcast on Thursday, May 4, 2017, at 8:30 a.m. Eastern Time, to provide an overview of its corporate and clinical...

XBIT : 4.99 (+11.38%)
XBiotech to Provide First Quarter 2017 Business Update

AUSTIN, Texas, April 28, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today it will host a conference call and live audio webcast on Thursday, May 4, 2017, at 8:30 a.m. Eastern Time,...

XBIT : 4.99 (+11.38%)
XBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at XBiotech, Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT).

XBIT : 4.99 (+11.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.

See More

Support & Resistance

2nd Resistance Point 4.79
1st Resistance Point 4.64
Last Price 4.99
1st Support Level 4.24
2nd Support Level 3.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.